Vertice Launches With Up To $300m For Specialty Pharma Deals
This article was originally published in Scrip
Executive Summary
While the big fish in the biopharma ocean are swallowing up all of the small fish, Vertice Pharma LLC is swimming against the tide with up to $300m from Warburg Pincus to support the startup's specialty pharmaceuticals strategy, starting with the acquisition of VistaPharm.
You may also be interested in...
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Imago Raises $80m Series C To Take Bomedemstat Into Phase III
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
Need a specific report? 1000+ reports available
Buy Reports